Zhang Y, Jiang Q, Dudus L, Yankaskas J R, Engelhardt J F
Department of Anatomy and Cell Biology, University of Iowa Medical Center, Iowa City 52242, USA.
Hum Gene Ther. 1998 Mar 20;9(5):635-48. doi: 10.1089/hum.1998.9.5-635.
Cystic fibrosis (CF) lung disease has been linked to multiple primary defects in airway epithelia caused by a dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) gene. These defects include altered Cl- and Na+ permeability as well as intracellular defects in glycoprotein processing. This apparent diversity in CFTR function is reflected in the complex patterning of CFTR expression in airway epithelia. Such complexities present challenges in the design of CF gene therapies that are capable of reconstituting the endogenous patterns of CFTR gene expression in appropriate target cells. Using a human bronchial xenograft model of the CF airway, we have evaluated the efficacy of recombinant adenoviral and cationic liposome-mediated gene transfer to correct Cl- permeability and mucous sulfation defects found in CF lung disease. Results from these studies demonstrated a clear vector-specific complementation profile for these two defects that was dependent on the type of cell transduced and the level of transgene expression. Single-dose administration of recombinant adenovirus effectively transduced high levels of CFTR transgene expression in 11 +/- 1% of epithelial cells and was capable of correcting cAMP-induced changes in Cl- permeability to 91 +/- 14% that seen in non-CF airways. However, this level of transgene expression was incapable of reversing defects in mucous sulfation due to the lack of efficient targeting to goblet cells. In contrast, cationic liposome-mediated delivery of CFTR encoding plasmids to CF airways achieved extremely low levels of transgene expression with insignificant correction (7.4 +/- 2.4%) of cAMP-induced Cl- permeability. This low level of transgene expression, however, efficiently reduced mucous sulfation to levels seen in non-CF airways. Differences in the complementation profiles of these two vectors in correcting Cl- permeability and mucous sulfation defects mirror the ability of recombinant adenovirus and liposomes to reconstitute only certain features of the endogenous distribution and abundance of CFTR protein expression. Such findings suggest that the level of intracellular CFTR required to facilitate proper glycoprotein processing may be much lower than that needed to mediate bulk Cl- flow across the airway epithelium. In summary, these data present the first example by which two different vector systems can efficiently complement independent primary defects associated with a single dysfunctional gene.
囊性纤维化(CF)肺部疾病与囊性纤维化跨膜传导调节因子(CFTR)基因功能失调导致的气道上皮细胞多种原发性缺陷有关。这些缺陷包括氯离子(Cl-)和钠离子(Na+)通透性改变以及糖蛋白加工过程中的细胞内缺陷。CFTR功能的这种明显多样性反映在气道上皮细胞中CFTR表达的复杂模式上。这种复杂性给CF基因治疗的设计带来了挑战,因为CF基因治疗需要在适当的靶细胞中重建CFTR基因表达的内源性模式。利用CF气道的人支气管异种移植模型,我们评估了重组腺病毒和阳离子脂质体介导的基因转移纠正CF肺部疾病中发现的Cl-通透性和黏液硫酸化缺陷的疗效。这些研究结果表明,这两种缺陷存在明显的载体特异性互补模式,这取决于转导的细胞类型和转基因表达水平。单剂量给予重组腺病毒可有效转导11±1%的上皮细胞高水平的CFTR转基因表达,并能将cAMP诱导的Cl-通透性变化纠正至非CF气道中所见的91±14%。然而,由于缺乏对杯状细胞的有效靶向,这种转基因表达水平无法逆转黏液硫酸化缺陷。相比之下,阳离子脂质体介导的CFTR编码质粒向CF气道的递送实现了极低水平的转基因表达,对cAMP诱导的Cl-通透性的纠正作用不显著(7.4±2.4%)。然而,这种低水平的转基因表达有效地将黏液硫酸化降低至非CF气道中所见的水平。这两种载体在纠正Cl-通透性和黏液硫酸化缺陷方面的互补模式差异反映了重组腺病毒和脂质体仅重建CFTR蛋白表达内源性分布和丰度某些特征的能力。这些发现表明,促进糖蛋白正确加工所需的细胞内CFTR水平可能远低于介导大量Cl-穿过气道上皮所需的水平。总之,这些数据首次证明了两种不同的载体系统可以有效互补与单个功能失调基因相关的独立原发性缺陷。